{"id":"gsk-investigational-vaccine-gsk2340269a","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vaccine candidate in development by GlaxoSmithKline, GSK2340269A likely works by priming the adaptive immune system to recognize and attack cells expressing particular antigens. The exact antigenic target and immunological approach (e.g., viral vector, protein subunit, nucleic acid platform) are not publicly detailed in widely available sources, limiting specificity of the mechanism description.","oneSentence":"GSK2340269A is an investigational vaccine designed to stimulate immune responses against specific tumor-associated antigens or infectious disease targets.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:33.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT00968539","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":130},{"nctId":"NCT00989287","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-07","conditions":"Influenza","enrollment":131},{"nctId":"NCT00951041","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-11","conditions":"Influenza","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK investigational vaccine GSK2340269A","genericName":"GSK investigational vaccine GSK2340269A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340269A is an investigational vaccine designed to stimulate immune responses against specific tumor-associated antigens or infectious disease targets. Used for Investigational indication under Phase 3 evaluation (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}